Safety and Tolerability of Cannabidivarin (CBDV) in Children and Young Adults With Autism Spectrum Disorder
Status:
Terminated
Trial end date:
2020-05-26
Target enrollment:
Participant gender:
Summary
To determine the safety and tolerability of GWP42006 (cannabidivarin, CBDV) in children and
young adults with autism spectrum disorder (ASD) and to examine the effect of GWP42006 on
communication, social interactions, sleep, behavior, and cognition profiles.